SCHEMBL1784577

SCHEMBL1784577

Cc1nc(NC(=O)NCCO)sc1-c1ccc(S(C)(=O)=O)cc1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 20/20 0.69
PIK3CG P48736 19/20 0.69
PIK3CA P42336 15/20 0.69
PIK3CB P42338 14/20 0.69
PI4KB Q9UBF8 4/20 0.53
CLK2 P49760 2/20 0.49
CLK1 P49759 1/20 0.49
PIK3C3 Q8NEB9 2/20 0.49
PIK3C2A O00443 1/20 0.49
PIK3C2B O00750 1/20 0.49
PI4KA P42356 1/20 0.49
PRKDC P78527 1/20 0.49
DYRK3 O43781 1/20 0.44
MAP4K4 O95819 1/20 0.44
DYRK1A Q13627 1/20 0.44
MINK1 Q8N4C8 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789273 0.93 PIK3CD (0.66) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1785827 0.92 PIK3CD (0.65) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL49803 0.89 PIK3CD (0.66) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48623 0.88 PIK3CD (0.72) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1786769 0.87 PIK3CD (0.64) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48850 0.86 PIK3CD (0.69) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48519 0.85 PIK3CD (0.61) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1786151 0.84 PIK3CD (0.76) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL12991289 0.83 PIK3CG (0.54) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48832 0.83 PIK3CD (0.75) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases NOVARTIS AG (CH) 2008-11-13 US claimed
US-20110124624-A1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2011-05-26 US disclosed
US-20110124693-A1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2011-05-26 US disclosed
US-7902375-B2 Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis NOVARTIS AG (CH) 2011-03-08 US disclosed
CN-1838953-B Phosphatidylinositol 3-kinase (PI) for the treatment of inflammatory airway diseases3) Inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives NOVARTIS AG 2011-02-02 CN disclosed
EP-1689391-B1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES NOVARTIS AG (CH) 2009-04-22 EP disclosed
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases NOVARTIS AG (CH) 2008-11-13 US disclosed
CN-1838953-A Phosphatidylinositol 3-kinase (PI3) inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives for the treatment of inflammatory airway diseases NOVARTIS AG (CH) 2006-09-27 CN disclosed
EP-1689391-A2 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES Novartis AG (CH) 2006-08-16 EP disclosed
WO-2005021519-A2 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES NOVARTIS AG (CH) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124693-A1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES PIK3CA, JAK2, JAK1 PIK3CD 12/4885PIK3CG 6/4885PIK3CA 1/4885
US-20110124624-A1 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES PIK3CA, JAK2, JAK3 PIK3CD 10/4885PIK3CG 6/4885PIK3CA 1/4885
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases PI4KA, IP6K3, PHOSPHO1 PIK3CD 26/4885PIK3CG 23/4885PIK3CA 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.